Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (RVMD) is a clinical-stage biotechnology company pioneering targeted therapies for cancers driven by RAS mutations. This page serves as the definitive source for verified news and developments related to the company's precision oncology programs.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and scientific advancements in RAS pathway inhibition. Our curated collection includes press releases on drug discovery breakthroughs, partnership announcements, and peer-reviewed research findings.
Key focus areas include updates on the company's RAS(ON) inhibitor portfolio, mTOR signaling developments, and strategic collaborations advancing cancer treatment innovation. All content is vetted for accuracy and relevance to provide reliable insights into RVMD's evolving pipeline.
Bookmark this page for structured access to essential updates about Revolution Medicines' progress in addressing unmet needs in oncology through its evolution-inspired therapeutic approaches.
Revolution Medicines (RVMD) reported its Q4 and full year 2024 financial results, highlighting progress in its RAS-focused cancer drug development programs. The company ended Q4 2024 with a net loss of $194.6M, compared to $161.5M in Q4 2023, while full-year 2024 net loss was $600.1M.
Key developments include advancing Phase 3 trials for daraxonrasib in pancreatic and lung cancers. The company expects to complete enrollment in the RASolute 302 trial for metastatic pancreatic cancer in 2025, with data readout in 2026. Two additional registrational trials for pancreatic cancer are planned for H2 2025.
Financially, RVMD strengthened its position through an $823M public equity offering in December 2024, ending the year with $2.3B in cash. The company projects 2025 GAAP net loss between $840M-$900M and expects current funds to support operations into H2 2027.
Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in three major investor conferences in March 2025.
The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will participate in fireside chats at:
- TD Cowen 45th Annual Healthcare Conference on March 3 at 1:50 p.m. ET
- Barclays 27th Annual Global Healthcare Conference on March 11 at 8:00 a.m. ET
- 2025 Leerink Partners Global Healthcare Conference on March 12 at 2:20 p.m. ET
Live webcasts of these events will be available on the company's investor relations website, with replays accessible for at least 14 days following the presentations.
Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced it will release its fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. The company's senior management will host a webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update. The webcast will be accessible through the company's investor relations website, with a replay available for at least 14 days following the live presentation.
Revolution Medicines (RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 10:30 a.m. ET.
The presentation will be accessible via live webcast through the company's investor relations website under the 'Events & Presentations' section. Interested parties can view a replay of the webcast on the same platform for at least 14 days following the conference.
Revolution Medicines (RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will deliver a corporate presentation on Monday, January 13, 2025, at 10:30 a.m. PT.
The presentation will be accessible via live webcast through the company's investor relations website under the 'Events & Presentations' section. A replay of the presentation will remain available on the website for a minimum of 14 days following the conference.
Revolution Medicines (RVMD) has successfully closed its upsized public offering, raising $862.5 million in gross proceeds. The offering consisted of 16,576,088 shares of common stock at $46.00 per share and pre-funded warrants to purchase 2,173,917 shares at $45.9999 per share. The total includes 2,445,652 additional shares from the full exercise of the underwriters' option.
The offering was managed by J.P. Morgan, TD Cowen, Goldman Sachs & Co. , and Guggenheim Securities as joint book-running managers, with UBS Investment Bank acting as lead manager.
Revolution Medicines (RVMD) has announced the pricing of an upsized public offering totaling $750.0 million. The offering consists of 14,130,436 shares of common stock priced at $46.00 per share, and pre-funded warrants to purchase 2,173,917 shares at $45.9999 per warrant. The company has granted underwriters a 30-day option to purchase up to an additional 2,445,652 shares. The offering, expected to close on December 5, 2024, is being managed by J.P. Morgan, TD Cowen, Goldman Sachs & Co. , and Guggenheim Securities as joint book-running managers, with UBS Investment Bank acting as lead manager.
Revolution Medicines (Nasdaq: RVMD), a clinical-stage oncology company, has announced a public offering of common stock worth up to $600.0 million. The company plans to grant underwriters a 30-day option to purchase an additional $90.0 million of shares. J.P. Morgan, TD Cowen, Goldman Sachs & Co. and Guggenheim Securities will serve as joint book-running managers, with UBS Investment Bank as lead manager. The offering's completion depends on market conditions, with no guaranteed timeline or final terms.
Revolution Medicines announced clinical updates from its RAS(ON) inhibitor portfolio, highlighting progress in treating RAS-addicted cancers. The company reported compelling Phase 1/1b data for RMC-6236 in pancreatic cancer and non-small cell lung cancer. In pancreatic cancer patients, RMC-6236 showed a 36% objective response rate for KRAS G12X mutations. The drug demonstrated favorable safety profiles both as monotherapy and in combinations with pembrolizumab. Initial antitumor activity was observed in colorectal cancer patients using RMC-6236 and RMC-6291 combination therapy. The company plans to initiate Phase 3 trials, including RASolve 301 in Q1 2025.
Revolution Medicines (Nasdaq: RVMD) has announced a forthcoming investor webcast to provide clinical updates on their RAS(ON) inhibitor portfolio. The event, focused on their targeted therapies for RAS-addicted cancers, is scheduled for December 2, 2024, at 8:00 a.m. Eastern Time. The webcast will be accessible online, with a replay available on the company's website's Events & Presentations page for at least 14 days after the live event.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
